Cameron Turtle insider trades: Spyre Therapeutics (SYRE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Cameron reports to the SEC
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | SYRE | ↓ Sell | 15,000 | $92.01 | $1.4M | Direct | Oct 2, 2026 (1d) |
| Sep 1, 2026 | SYRE | ↓ Sell | 15,000 | $87.29 | $1.3M | Direct | Sep 3, 2026 (2d) |
| Aug 3, 2026 | SYRE | ↓ Sell | 15,000 | $95.51 | $1.4M | Direct | Aug 5, 2026 (2d) |
| Jul 1, 2026 | SYRE | ↓ Sell | 15,000 | $87.69 | $1.3M | Direct | Jul 2, 2026 (1d) |
| Jun 1, 2026 | SYRE | ↓ Sell | 15,000 | $70.43 | $1.1M | Direct | Jun 3, 2026 (2d) |
| May 1, 2026 | SYRE | ↓ Sell | 15,000 | $71.37 | $1.1M | Direct | May 1, 2026 (0d) |
| Apr 1, 2026 | SYRE | ↓ Sell | 15,000 | $49.33 | $740K | Direct | Apr 3, 2026 (2d) |
| Mar 2, 2026 | SYRE | ↓ Sell | 15,000 | $42.19 | $633K | Direct | Mar 3, 2026 (1d) |
| Feb 2, 2026 | SYRE | ↓ Sell | 15,000 | $32.80 | $492K | Direct | Feb 4, 2026 (2d) |
| Jan 2, 2026 | SYRE | ↓ Sell | 15,000 | $30.68 | $460K | Direct | Jan 6, 2026 (4d) |
| Dec 1, 2025 | SYRE | ↓ Sell | 15,000 | $29.02 | $435K | Direct | Dec 3, 2025 (2d) |
| Nov 3, 2025 | SYRE | ↓ Sell | 45,000 | $23.33 | $1.0M | Direct | Nov 5, 2025 (2d) |
| Dec 28, 2020 | BBIO | ↓ Sell | 19,500 | $69.60 | $1.4M | Direct | Dec 29, 2020 (1d) |
| Dec 15, 2020 | EIDX | ↓ Sell | 26,294 | $111.77 | $2.9M | Direct | Dec 16, 2020 (1d) |
| Nov 25, 2020 | BBIO | ↓ Sell | 5,000 | $47.04 | $235K | Direct | Nov 25, 2020 (0d) |
| Nov 11, 2020 | EIDX | ↓ Sell | 13,410 | $74.51 | $999K | Direct | Nov 13, 2020 (2d) |
| Nov 5, 2020 | BBIO | ↓ Sell | 2,500 | $42.05 | $105K | Direct | Nov 9, 2020 (4d) |
| Nov 2, 2020 | EIDX | ↓ Sell | 12,500 | $70.72 | $884K | Direct | Nov 3, 2020 (1d) |
| Sep 30, 2020 | BBIO | ↓ Sell | 14,500 | $37.69 | $546K | Direct | Oct 2, 2020 (2d) |
| Sep 18, 2020 | BBIO | ↓ Sell | 2,500 | $42.01 | $105K | Direct | Sep 22, 2020 (4d) |
| Sep 15, 2020 | BBIO | ↓ Sell | 2,500 | $37.06 | $93K | Direct | Sep 16, 2020 (1d) |
| Sep 11, 2020 | BBIO | ↓ Sell | 2,000 | $35.02 | $70K | Direct | Sep 15, 2020 (4d) |
| Sep 10, 2020 | EIDX | ↓ Sell | 2,500 | $47.00 | $118K | Direct | Sep 11, 2020 (1d) |
| Aug 3, 2020 | EIDX | ↓ Sell | 10,000 | $39.94 | $399K | Direct | Aug 5, 2020 (2d) |
| Jun 30, 2020 | BBIO | ↓ Sell | 10,000 | $32.66 | $327K | Direct | Jul 2, 2020 (2d) |
| May 26, 2020 | EIDX | ↓ Sell | 2,500 | $47.00 | $118K | Direct | May 28, 2020 (2d) |
| May 1, 2020 | EIDX | ↓ Sell | 10,000 | $40.84 | $408K | Direct | May 5, 2020 (4d) |
| Apr 27, 2020 | BBIO | ↓ Sell | 2,000 | $32.01 | $64K | Direct | Apr 29, 2020 (2d) |
| Apr 8, 2020 | BBIO | ↓ Sell | 8,000 | $27.04 | $216K | Direct | Apr 10, 2020 (2d) |
| Feb 11, 2020 | BBIO | ↓ Sell | 2,000 | $37.28 | $75K | Direct | Feb 13, 2020 (2d) |
| Feb 3, 2020 | EIDX | ↓ Sell | 12,500 | $53.65 | $671K | Direct | Feb 5, 2020 (2d) |
| Jan 8, 2020 | BBIO | ↓ Sell | 12,807 | $34.37 | $440K | Direct | Jan 10, 2020 (2d) |
| Dec 6, 2019 | EIDX | ↓ Sell | 10,000 | $59.25 | $592K | Direct | Dec 10, 2019 (4d) |
| Nov 20, 2019 | EIDX | ↓ Sell | 10,000 | $55.75 | $558K | Direct | Nov 22, 2019 (2d) |
| Sep 4, 2019 | EIDX | ↓ Sell | 5,000 | $41.58 | $208K | Direct | Sep 6, 2019 (2d) |
| Jun 4, 2019 | EIDX | ↓ Sell | 10,000 | $31.64 | $316K | Direct | Jun 6, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SYRE insiders
Open-market trades in the last 12 months
About Cameron Turtle's insider trades
Cameron Turtle is Chief Executive Officer at Spyre Therapeutics (SYRE). Since Jun 4, 2019, Cameron has reported no open-market purchases and 36 sales worth $23.2M on SEC Form 4. In the last 12 months: 11 sales ($10.3M).
Their filings also include option exercises (21 filings), grants and awards (10 filings), conversions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SYRE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.